Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC

March 15, 2021
OncLive Staff

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Amgen, we had the pleasure of speaking with Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, to discuss the significance of data presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with sotorasib in KRAS G12C-mutant solid tumors.

In our exclusive interview, Spira discussed the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.


x